New choice of first line immunotherapy for non squamous lung cancer! Roche tumor immunotherapy tecentriq + chemotherapy program has been approved by the US FDA!

December 6, 2019 / BIOON/ --Roche, a Swiss pharmaceutical giant, recently announced that the U.S Food and Drug Administration (FDA) has approved the first-line treatment of metastatic non squamous non-small cell lung cancer (NSQ NSCLC) in adults without EGFR and alk genomic tumor distortion by combining chemotherapy (carboplatin and Abraxane) In the European Union, tecentriq's treatment was approved in early September This approval is based on data from phase III clinical study impower 130 (nct02367781) This study showed that tecentriq combined chemotherapy significantly prolonged the overall survival (median OS: 18.6 months vs 13.9 months; HR = 0.80; 95% CI: 0.64 – 0.99; P = 0.0384), significantly reduced the risk of disease progression or death by 35% (median progression free survival [PFS]: 7.2 months vs 6.5 months; HR = 0.75; 95% CI: 0.63-0.91, P = 0.0024) In this study, the safety of tecentriq combined chemotherapy was consistent with the known safety of each drug component 73.2% of the patients who received tecentriq combined therapy experienced grade 3-4 treatment-related adverse events, compared with 60.3% of the patients in the chemotherapy group In terms of lung cancer, tecentriq has been approved by the US FDA: (1) in combination with Avastin (general name: bevacizumab, bevacizumab) and chemotherapy (paclitaxel + carboplatin), the first-line treatment of metastatic non squamous non-small cell lung cancer (NSQ) without EGFR or ALK genomic tumor distortion NSCLC) adult patients; (2) for the treatment of metastatic NSCLC adult patients during or after chemotherapy with platinum, tecentriq is only applicable to patients carrying EGFR or ALK genomic tumor aberrations after the failure of the approved targeted therapy (3) Combined chemotherapy (carboplatin + etoposide) is a first-line treatment for adult patients with extensive small cell lung cancer (es-sclc) Levi Garraway, MD, chief medical officer and head of global product development of Roche, said: "we are pleased to provide this tecentriq based combination treatment for patients with NSCLC, as a new treatment scheme, which can provide patients with clinically significant survival benefits Today's approval provides another opportunity to help extend the lives of people with this disease " According to the World Health Organization (who), lung cancer is the leading cause of cancer death in the world It causes nearly 1.8 million deaths every year, which means more than 4800 people die every day There are two main types of lung cancer, among which NSCLC accounts for 85% of lung cancer cases Although NSCLC treatment has made progress in recent years, new treatment options are still needed to support customized treatment for this complex disease Tecentriq belongs to PD - (L) 1 tumor immunotherapy Atezolizumab, the active drug component of the drug, is a monoclonal antibody, targeting to bind PD-L1 protein expressed on tumor cells and tumor infiltrating immune cells, blocking its interaction with PD-1 and B7.1 receptors Tecentriq can activate T cells by inhibiting PD-L1 Tecentriq has the potential to be a basic combination therapy for cancer immunotherapy, targeted drugs and various cancer chemotherapy programs In lung cancer, Roche is conducting a number of phase III studies to evaluate tecentriq as a single drug therapy or combination therapy with other drugs Up to now, tecentriq has been approved in the United States, the European Union and other countries in the world as a single drug therapy, as well as combined targeted therapy and / or chemotherapy, to treat various types of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), some types of metastatic urothelial cancer (MUC), PD-L1 positive triple negative breast cancer (TNBC) In China, at the end of November this year, keytruda (coreida, common name: pembrolizumab, mAb) was approved by the National Drug Administration (nmpa) to treat metastatic squamous non-small cell lung cancer (NSCLC) patients with carboplatin and paclitaxel as the first-line therapy It is worth mentioning that in less than a year, keytruda has been approved as the third first-line treatment indication in the field of NSCLC in China, which also marks that the drug has become the first and only one in China that can treat both squamous and non squamous NSCLC patients within the corresponding indication range by combining chemotherapy first-line treatment and NSC within the corresponding indication range by single drug first-line treatment Tumor immunotherapy drugs for LC patients Specifically: (1) keytruda combined with carboplatin and paclitaxel is suitable for the first-line treatment of patients with metastatic non-small cell lung cancer; (2) keytruda combined with pemetrexed and platinum chemotherapy is suitable for the first-line treatment of EGFR gene mutation negative and alk negative metastatic non-small cell lung cancer; (3) keytruda is suitable for the first-line treatment of metastatic non-small cell lung cancer; (3) keytruda is suitable for Nmpa approved tests evaluated PD-L1 tumor fraction (TPS) ≥ 1% EGFR gene mutation negative and anaplastic lymphoma kinase (ALK) negative local advanced or metastatic non-small cell lung cancer as first-line monotherapy Original source: FDA Approves Roche's tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metallic non squamous non small cell lung cancer